Edwards Lifesciences Corp (EW) KPIs and segments
Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Edwards Lifesciences · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)
Nhìn nhanh KPI của Edwards Lifesciences: 39 chỉ số vận hành, trong đó có Total Continuing Operations Net Sales, Transcatheter Aortic Valve Replacement Sales và Transcatheter Mitral and Tricuspid Therapies Sales, lấy từ 241 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States($M) | 1,004 | 938 | 907 | 908 | 890 | 839 | 813 | 805 | 806 | 782 | 744 | ||
Europe($M) | 440 | 443 | 410 | 388 | 378 | 342 | 344 | 320 | 332 | 326 | 302 | ||
Rest of World($M) | 202 | 178 | 166 | 168 | 169 | 150 | 143 | 149 | 144 | 136 | 132 | ||
Japan($M) | 96.4 | 90.6 | 87.5 | 90.1 | 95.3 | 81.8 | 85.9 | 81.4 | 86.5 | 86 | 99.3 | ||
Transcatheter Aortic Valve Replacement($M) | 1,258 | 1,197 | 1,160 | 1,150 | 1,131 | 1,047 | 1,036 | 1,023 | 1,039 | 1,008 | 979 | ||
Surgical($M) | 284 | 276 | 267 | 251 | |||||||||
Surgical Structural Heart($M) | 254 | 258 | 267 | 251 | 244 | 240 | 248 | 249 | 231 | ||||
Transcatheter Mitral and Tricuspid Therapies($M) | 199 | 175 | 156 | 145 | 135 | 115 | 105 | 91.1 | 83 | 72.9 | 56 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
United States($M) | 818 | 766 | 767 | 740 | 722 | 693 | 679 | 678 | 660 | 642 | |||
Europe($M) | 346 | 349 | 319 | 306 | 293 | 260 | 265 | 247 | 258 | 252 | |||
Rest of World($M) | 146 | 130 | 119 | 127 | 125 | 110 | 105 | 108 | 104 | 97.4 | |||
Japan($M) | 81.1 | 76.3 | 74.3 | 76.8 | 81.7 | 69.5 | 73.9 | 69.7 | 73.9 | 74.2 | |||
United States($M) | 653 | 611 | 601 | 600 | 586 | 559 | 540 | 551 | 542 | 527 | 498 | ||
Europe($M) | 232 | 235 | 191 | 207 | 204 | 195 | 185 | 177 | 186 | 177 | 166 | ||
Rest of World($M) | 103 | 89.7 | 54.3 | 82 | 84.7 | 77.5 | 58.3 | 67.2 | 60.4 | 57.1 | 58.4 | ||
Japan($M) | 73.5 | 66.4 | 52.9 | 59.8 | 63.4 | 57.7 | 53.6 | 54.4 | 57.9 | 47.5 | 54.3 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)4 | |||||||||||||
Total Continuing Operations Net Sales (Product Reconciliation)($M)5 | 1,716 | 1,741 | 1,649 | 1,570 | 1,553 | 1,532 | 1,413 | 1,386 | 1,354 | 1,632 | 1,598 | 1,534 | |
Total Sales Constant Currency / Underlying YoY Growth(%) | 11.2% | 12.5% | 12.7% | 11.6% | 12.6% | 10.6% | 7.9% | 8.8% | 9.6% | 7.9% | 9.9% | 13.0% | |
Total Sales GAAP YoY Growth(%) | 10.5% | 13.6% | 16.7% | 13.3% | 14.7% | 11.9% | 6.2% | 9.4% | 8.9% | 6.7% | 9.5% | 13.8% | |
Total Sales YoY Dollar Change($M) | 162 | 209 | 236 | 184 | 199 | 163 | 82.8 | 119 | 111 | 102 | 139 | 186 | |
Total Sales Foreign Exchange (FX) Impact($M) | -9.80 | 14.8 | 49.2 | 20.1 | 24.4 | 15.4 | -21.5 | 7.10 | -7.90 | -17.6 | -5.10 | 9.30 | |
Total Sales Prior-Year Constant-Currency Adjusted Base($M) | 1,543 | 1,547 | 1,462 | 1,406 | 1,379 | 1,385 | 1,308 | 1,274 | 1,236 | 1,513 | 1,455 | 1,358 | |
Transcatheter Aortic Valve Replacement (TAVR) Sales($M)5 | 1,242 | 1,258 | 1,197 | 1,160 | 1,150 | 1,131 | 1,047 | 1,036 | 1,023 | 1,039 | 1,008 | 979 | |
TAVR Constant Currency / Underlying YoY Growth(%) | 8.8% | 10.5% | 11.0% | 10.6% | 10.6% | 7.8% | 5.4% | 5.3% | 7.2% | 5.8% | 6.6% | 12.1% | |
TAVR GAAP YoY Growth(%) | 8.0% | 11.3% | 14.4% | 12.0% | 12.4% | 8.9% | 3.8% | 5.8% | 6.5% | 4.7% | 6.3% | 12.9% | |
TAVR YoY Sales Dollar Change($M) | 91.7 | 127 | 151 | 124 | 127 | 92.3 | 38.7 | 56.9 | 62.4 | 47 | 60 | 112 | |
TAVR Foreign Exchange (FX) Impact($M) | -7.90 | 8.40 | 32 | 13.5 | 17 | 11.3 | -15.1 | 4.80 | -5.90 | -10.4 | -2.10 | 5.80 | |
TAVR Prior-Year Constant-Currency Adjusted Base Sales($M) | 1,142 | 1,139 | 1,079 | 1,050 | 1,040 | 1,050 | 993 | 984 | 955 | 981 | 946 | 874 | |
Transcatheter Mitral and Tricuspid Therapies (TMTT) Sales($M)6 | 210 | 199 | 175 | 156 | 145 | 135 | 115 | 105 | 91.1 | 83 | 72.9 | 56 | |
TMTT Constant Currency / Underlying YoY Growth(%) | 45.9% | 45.2% | 42.8% | 44.1% | 53.2% | 57.1% | 61.4% | 85.0% | 73.7% | 74.7% | 72.2% | 71.1% | |
TMTT GAAP YoY Growth(%) | 44.3% | 47.7% | 51.9% | 48.3% | 59.3% | 61.9% | 58.1% | 87.7% | 73.4% | 74.7% | 75.2% | 77.6% | |
TMTT YoY Sales Dollar Change($M) | 64.3 | 64.1 | 59.9 | 50.6 | 54.1 | 51.5 | 42.3 | 49.1 | 38.7 | 35.4 | 31.3 | 24.5 | |
TMTT Foreign Exchange (FX) Impact($M) | -1.50 | 2.40 | 7.40 | 2.90 | 3 | 1.70 | -1.80 | 0.80 | 0 | 0 | 0.70 | 1.30 | |
TMTT Prior-Year Constant-Currency Adjusted Base Sales($M) | 144 | 137 | 123 | 108 | 94.1 | 84.7 | 71.1 | 56.8 | 52.4 | 47.6 | 42.3 | 32.8 | |
Implantable Heart Failure Management (IHFM / Cordella) Sales Included in TMTT($M) | 2.90 | 2.70 | 2 | 2.10 | 1.70 | 1.50 | 0.40 | ||||||
Surgical Structural Heart Sales($M)6 | 264 | 284 | 276 | 254 | 258 | 267 | 251 | 244 | 240 | 264 | 266 | 248 | |
Surgical Constant Currency / Underlying YoY Growth(%) | 2.8% | 5.0% | 5.9% | 2.2% | 5.6% | 6.8% | 2.6% | 5.1% | 5.1% | 4.6% | 7.9% | 9.9% | |
Surgical GAAP YoY Growth(%) | 2.5% | 6.5% | 10.1% | 3.8% | 7.5% | 7.7% | 0.7% | 5.8% | 4.3% | 3.1% | 7.2% | 10.8% | |
Surgical YoY Sales Dollar Change($M) | 6.40 | 17.3 | 25.3 | 9.20 | 18 | 19 | 1.80 | 13.4 | 9.90 | 8 | 17.9 | 24.1 | |
Surgical Foreign Exchange (FX) Impact($M) | -0.40 | 4 | 9.80 | 3.70 | 4.40 | 2.40 | -4.60 | 1.50 | -2 | -3.60 | -1.40 | 1.70 | |
Surgical Prior-Year Constant-Currency Adjusted Base Sales($M) | 258 | 271 | 261 | 248 | 244 | 250 | 245 | 233 | 228 | 253 | 247 | 226 | |
Transitional Service Agreement (TSA) Revenue Included in Surgical($M) | 1.50 | 2.30 | 3 | ||||||||||
Critical Care Sales (Legacy — Divested Sept 3, 2024)5 | |||||||||||||
Critical Care Constant Currency / Underlying YoY Growth (Legacy)(%) | 14.4% | 11.0% | |||||||||||
Critical Care GAAP YoY Growth (Legacy)(%) | 13.3% | 11.3% | |||||||||||
Critical Care YoY Sales Dollar Change (Legacy)($M) | 29.4 | 25.5 | |||||||||||
Critical Care Foreign Exchange (FX) Impact (Legacy)($M) | -2.30 | 0.50 | |||||||||||
Critical Care Prior-Year Constant-Currency Adjusted Base Sales (Legacy)($M) | 220 | 226 | |||||||||||
United States Net Sales($M)4 | 1,008 | 1,004 | 938 | 907 | 908 | 890 | 839 | 813 | 805 | 149 | 941 | 894 | |
United States Constant Currency / Underlying YoY Growth(%) | 11.0% | 12.8% | 11.8% | 11.6% | 12.6% | 10.1% | 7.2% | 9.2% | 9.3% | 11.8% | 10.8% | 12.4% | |
United States GAAP YoY Growth(%) | 11.0% | 12.8% | 11.8% | 11.6% | 12.8% | 10.3% | 7.3% | 9.2% | 9.3% | 11.8% | 10.8% | 12.4% | |
United States YoY Sales Dollar Change($M) | 100 | 114 | 98.7 | 94.1 | 103 | 83.3 | 56.8 | 68.6 | 68.7 | 15.7 | 91.6 | 98.9 | |
United States Prior-Year Adjusted Base Sales($M) | 908 | 890 | 839 | 813 | 805 | 806 | 782 | 744 | 736 | 133 | 849 | 796 | |
Outside of the United States (Total International / OUS) Net Sales($M)5 | 708 | 738 | 711 | 663 | 646 | 643 | 574 | 573 | 550 | 97.3 | 658 | 640 | |
OUS Constant Currency / Underlying YoY Growth(%) | 11.5% | 12.2% | 14.1% | 11.7% | 12.5% | 11.3% | 9.0% | 8.2% | 10.0% | -0.3% | 8.6% | 13.7% | |
OUS GAAP YoY Growth(%) | 9.7% | 14.8% | 23.9% | 15.6% | 17.4% | 14.1% | 4.8% | 9.7% | 8.4% | -4.0% | 7.7% | 15.7% | |
OUS YoY Sales Dollar Change($M) | 62.3 | 95 | 137 | 89.7 | 95.8 | 79.5 | 26 | 50.8 | 42.3 | -4 | 47 | 86.9 | |
OUS Foreign Exchange (FX) Impact($M) | -9.80 | 14.8 | 49.2 | 20.1 | 24.4 | 15.4 | -21.5 | 7.10 | -7.90 | -3.60 | -5.10 | 9.30 | |
OUS Prior-Year Constant-Currency Adjusted Base Sales($M) | 636 | 657 | 623 | 593 | 574 | 578 | 526 | 529 | 500 | 97.7 | 605 | 562 | |
Europe Net Sales($M)5 | 415 | 440 | 443 | 410 | 388 | 378 | 342 | 344 | 320 | 36.9 | 368 | 345 | |
Europe Constant Currency / Underlying YoY Growth(%) | 8.2% | 11.7% | 15.1% | 11.9% | 14.0% | 9.6% | 8.8% | 10.7% | 11.4% | 7.4% | 8.4% | 13.0% | |
Europe GAAP YoY Growth(%) | 6.9% | 16.2% | 29.5% | 19.1% | 21.3% | 13.8% | 4.9% | 13.6% | 11.6% | 7.7% | 11.1% | 18.7% | |
Europe YoY Sales Dollar Change($M) | 26.7 | 61.4 | 101 | 65.9 | 68.1 | 46 | 15.8 | 41.2 | 33.3 | 2.60 | 36.7 | 54.1 | |
Europe Foreign Exchange (FX) Impact($M) | -4.30 | 15.4 | 42.9 | 22.3 | 21.1 | 13.1 | -11.9 | 8 | 0.60 | 0.20 | 8.30 | 14.4 | |
Europe Prior-Year Constant-Currency Adjusted Base Sales($M) | 384 | 394 | 385 | 366 | 341 | 345 | 314 | 311 | 287 | 34.5 | 339 | 305 | |
Japan Net Sales($M)5 | 92 | 96.4 | 90.6 | 87.5 | 90.1 | 95.3 | 81.8 | 85.9 | 81.4 | 19.4 | 111 | 112 | |
Japan Constant Currency / Underlying YoY Growth(%) | 12.2% | 10.1% | 12.0% | 3.9% | 6.5% | 4.2% | -1.0% | 2.2% | 1.0% | -6.9% | 8.2% | 6.8% | |
Japan GAAP YoY Growth(%) | 2.2% | 1.1% | 10.8% | 1.9% | 10.6% | 10.2% | -4.9% | 1.8% | -5.1% | -18.8% | -2.8% | 0.7% | |
Japan YoY Sales Dollar Change($M) | 1.90 | 1.10 | 8.80 | 1.60 | 8.70 | 8.80 | -4.20 | 1.50 | -4.40 | -4.50 | -3.30 | 0.90 | |
Japan Foreign Exchange (FX) Impact($M) | -8.10 | -7.80 | -0.90 | -1.70 | 3.20 | 5.10 | -3.40 | -0.40 | -5.20 | -3 | -11.7 | -6.60 | |
Japan Prior-Year Constant-Currency Adjusted Base Sales($M) | 82 | 87.5 | 80.9 | 84.2 | 84.6 | 91.6 | 82.6 | 84 | 80.6 | 20.9 | 102 | 105 | |
Rest of World (ROW) Net Sales($M)5 | 201 | 202 | 178 | 166 | 168 | 169 | 150 | 143 | 149 | 41 | 179 | 183 | |
Rest of World Constant Currency / Underlying YoY Growth(%) | 18.3% | 14.4% | 13.0% | 15.9% | 12.7% | 19.5% | 15.9% | 6.4% | 12.7% | -3.0% | 9.4% | 19.9% | |
Rest of World GAAP YoY Growth(%) | 20.2% | 19.3% | 18.4% | 15.5% | 12.7% | 17.1% | 10.6% | 5.9% | 10.1% | -5.1% | 8.2% | 21.0% | |
Rest of World YoY Sales Dollar Change($M) | 33.7 | 32.5 | 27.6 | 22.2 | 19 | 24.7 | 14.4 | 8.10 | 13.4 | -2.10 | 13.6 | 31.9 | |
Rest of World Foreign Exchange (FX) Impact($M) | 2.60 | 7.20 | 7.20 | -0.50 | 0.10 | -2.80 | -6.20 | -0.50 | -3.30 | -0.80 | -1.70 | 1.50 | |
Rest of World Prior-Year Constant-Currency Adjusted Base Sales($M) | 170 | 176 | 157 | 143 | 149 | 142 | 130 | 135 | 132 | 42.3 | 164 | 152 | |
Operating Segments Total Cost of Sales (ASU 2023-07)($M)4 | 345 | 349 | 328 | 290 | 304 | 310 | 280 | 263 | 252 | 274 | 264 | ||
United States Segment Cost of Sales($M) | 183 | 185 | 172 | 140 | 167 | 168 | 146 | 134 | 127 | 146 | 140 | ||
Europe Segment Cost of Sales($M) | 93.8 | 93.4 | 93.6 | 90.7 | 82.4 | 84.8 | 82.2 | 78.4 | 72.7 | 74.4 | 73.6 | ||
Japan Segment Cost of Sales($M) | 15.2 | 15.3 | 14.3 | 13.2 | 13.3 | 13.6 | 12.3 | 12 | 11.7 | 12.6 | 11.8 | ||
Rest of World Segment Cost of Sales($M) | 53.4 | 55.2 | 47.6 | 46.1 | 40.8 | 43.9 | 39.8 | 38.4 | 41 | 40.3 | 38.4 | ||
Operating Segments Total Other Segment Items (SG&A, R&D & FX Adjustments)($M)4 | 12.2 | 22.8 | 29.2 | 22.1 | 24 | 7.70 | -21.5 | 0.40 | 0.30 | -5.10 | 4.40 | ||
United States Segment Other Segment Items($M) | 0.50 | 0.70 | 0.80 | 0.60 | 0.70 | 0.60 | 0.60 | 0.40 | 0.60 | 0.70 | 0.70 | ||
Europe Segment Other Segment Items($M) | 29 | 38.1 | 41.9 | 30.4 | 28.9 | 15.2 | -8.30 | 5.20 | 4.80 | 0.80 | 4.10 | ||
Japan Segment Other Segment Items($M) | -10 | -8.90 | -6 | -4.30 | -0.90 | -0.20 | -4.60 | -1.50 | -2.40 | -3.60 | 0.70 | ||
Rest of World Segment Other Segment Items($M) | -7.30 | -7.10 | -7.50 | -4.60 | -4.70 | -7.90 | -9.20 | -3.70 | -2.70 | -3 | -1.10 | ||
GAAP Gross Profit Margin (% of Net Sales)(%)6 | 78.5% | 77.5% | 78.0% | 78.1% | 77.8% | 77.5% | 78.7% | 78.9% | 80.6% | 79.4% | 75.9% | 76.7% | |
GAAP Selling, General & Administrative Expenses (% of Net Sales)(%) | 32.7% | 32.2% | 31.7% | 38.4% | 33.1% | 32.8% | 33.0% | 35.5% | 31.1% | 32.5% | 30.6% | 31.3% | |
GAAP Research & Development Expenses (% of Net Sales)(%) | 16.4% | 16.0% | 16.0% | 17.1% | 18.1% | 18.0% | 18.0% | 19.6% | 18.7% | 19.7% | 17.8% | 17.6% | |
GAAP Operating Income Margin (% of Net Sales)(%) | 17.4% | 29.5% | 29.0% | 9.6% | 19.8% | 26.8% | 27.9% | 22.6% | 25.9% | 26.6% | 24.2% | 26.1% | |
GAAP Income Before Taxes Margin (% of Net Sales)(%) | 21.2% | 29.9% | 27.8% | 5.8% | 22.4% | 26.1% | 30.7% | 28.1% | 29.7% | 27.9% | 25.6% | 27.5% | |
GAAP Net Income Margin (% of Net Sales)(%) | 17.6% | 13.9% | 23.1% | 4.1% | 18.8% | 21.9% | 25.7% | 24.9% | 26.7% | 26.4% | 22.0% | 24.1% | |
GAAP Effective Income Tax Rate(%) | 17.0% | 53.6% | 17.1% | 29.0% | 16.1% | 16.1% | 16.2% | 11.6% | 10.1% | 5.2% | 14.3% | 12.3% | |
Non-GAAP Adjusted Operating Income($M)5 | 521 | 523 | 518 | 373 | 427 | 433 | 411 | 355 | 426 | 509 | 439 | 428 | |
Non-GAAP Adjusted Gross Profit Margin(%) | 78.7% | 77.6% | 78.2% | 78.3% | 77.9% | 77.6% | 78.7% | 79.0% | 80.7% | 77.1% | 76.0% | 76.8% | |
Non-GAAP Adjusted Operating Profit Margin(%) | 30.3% | 30.0% | 31.4% | 23.7% | 27.5% | 28.2% | 29.1% | 25.6% | 31.4% | 31.2% | 26.9% | 28.2% | |
Non-GAAP Adjusted Net Income($M) | 459 | 448 | 455 | 338 | 390 | 392 | 379 | 349 | 399 | 425 | 397 | 390 | |
Non-GAAP Adjusted Diluted Earnings Per Share (EPS)($) | 0.80 | 0.78 | 0.78 | 0.58 | 0.67 | 0.67 | 0.64 | 0.59 | 0.67 | 0.70 | 0.66 | 0.64 | |
Non-GAAP Adjusted Effective Income Tax Rate(%) | 19.8% | 18.6% | 18.4% | 17.9% | 16.9% | 16.8% | 16.3% | 13.3% | 12.4% | 8.4% | 14.0% | 13.4% | |
Total Inventories, Net($M)4 | 1,159 | 1,131 | 1,119 | 1,126 | 1,141 | 1,142 | 1,114 | 1,087 | 1,104 | 1,025 | 1,207 | 904 | |
Finished Goods Inventory (Including Consigned Heart Valves)($M) | 711 | 686 | 674 | 677 | 642 | 631 | 595 | 609 | 611 | 554 | 669 | 511 | |
Consigned Inventory Held at Customer Hospital Sites($M) | 230 | 222 | 230 | 225 | 216 | 217 | 200 | 182 | 188 | 167 | 162 | 165 | |
Work in Process (WIP) Inventory($M) | 230 | 235 | 242 | 253 | 276 | 261 | 260 | 236 | 244 | 238 | 259 | 196 | |
Raw Materials Inventory($M) | 218 | 211 | 202 | 197 | 223 | 250 | 259 | 241 | 249 | 234 | 280 | 196 | |
Property, Plant and Equipment, Gross1 | |||||||||||||
Property, Plant and Equipment, Net($M) | 1,858 | 1,842 | 1,823 | 1,812 | 1,743 | 1,727 | 1,698 | 1,686 | 1,676 | 1,640 | 1,768 | 1,591 | |
Operating Lease Right-of-Use (ROU) Assets($M)2 | 100 | 100 | 99.3 | 103 | 96.5 | 99 | 96.9 | 98.2 | 104 | 92.8 | 98.4 | 84.4 | |
Operating Cash Flows Used for Operating Leases($M) | 7.60 | 7.70 | 7.30 | 7.40 | 7.40 | 7.50 | 7 | 7 | 6.50 | 7.20 | 7.30 | 6.60 | |
ROU Assets Obtained in Exchange for New Operating Lease Liabilities($M) | 6.20 | 8 | 3.60 | 12.7 | 4.60 | 5.50 | 3.20 | 3.90 | 14.3 | 16.9 | 7.70 | 7.40 | |
Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D)($M) | 1,161 | 1,383 | 1,228 | 1,128 | 1,131 | 1,173 | 1,175 | 1,177 | 956 | 417 | 447 | 399 | |
Accrued Clinical Trial & Research and Development Liabilities($M)5 | 69.1 | 69 | 69.8 | 69.2 | 75.3 | 74.4 | 74.9 | 74.1 | 79 | 78 | 75.7 | 71.6 | |
Accrued Customer Rebates, Product Returns and Sales Allowances($M) | 185 | 164 | 144 | 157 | 158 | 143 | 119 | 139 | 140 | 121 | 121 | 124 | |
Accrued Litigation & Insurance Reserves (Current)($M) | 37.1 | 72.4 | 75.9 | 164 | 105 | 26.4 | 28 | 26.8 | 29.5 | 32.5 | 32.9 | 28.9 | |
Allowance for Credit Losses (Doubtful Accounts Receivable)($M) | 17 | 16 | 15.6 | 15 | 12.6 | 12.7 | 12.6 | 11.6 | 12.6 | 13.9 | 13.5 | 8.20 | |
Total Litigation & IP Agreement Reserves (Current & Noncurrent)($M) | 21.3 | 56.9 | 57.3 | 146 | 85.5 | 10.5 | |||||||
Intellectual Property Litigation & Settlement Expenses, Net($M) | -12.7 | 6.30 | 37.1 | 209 | 90.4 | 15.5 | 10.9 | 12.6 | 10.8 | 8.10 | 8.90 | 9.90 | |
Total Common Shares Repurchased (Monthly & Quarterly)4 | 1,593,034 | 1,945,635 | 4,912,499 | 524,543 | 7,718,577 | 3,436,149 | 1,704,349 | 13,295,312 | 1,729,657 | 5,983,233 | |||
Common Shares Repurchased Under Publicly Announced Board Plans | 1,593,034 | 1,945,635 | 4,912,499 | 524,543 | 7,718,577 | 3,436,149 | 1,704,349 | 13,295,312 | 1,729,657 | 5,983,233 | |||
Remaining Dollar Value of Shares Authorized for Repurchase Under Board Plans($M) | 1,317 | 1,455 | 1,494 | 2,014 | 2,054 | 1,092 | 1,399 | 1,399 | 899 | 1,049 | |||
Cash Paid for Purchases of Treasury Stock($M) | 139 | 153 | 422 | 40.6 | 589 | 5.50 | 259 | 100 | 901 | 158 | 0.20 | 448 | |
Cumulative Treasury Shares Held(M) | 86.7 | 85.1 | 83 | 78 | 77.5 | 69.7 | 69.7 | 66.2 | 64.5 | 51.2 | 49.4 | 49.4 | |
Total Stock-Based Compensation (SBC) Expense($M)3 | 46 | 42.2 | 45.4 | 39.2 | 41.1 | 37.5 | 40.1 | 34.1 | 35.2 | 37.3 | 39 | 27.5 | |
SBC Expense, Net of Income Tax Benefit($M) | 37.4 | 35.2 | 37.9 | 31.6 | 33.3 | 31.4 | 33.6 | 26.8 | 29.2 | 31.3 | 33.5 | 20.2 | |
Income Tax Benefit Recognized for Stock-Based Compensation($M) | 8.60 | 7 | 7.50 | 7.60 | 7.80 | 6.10 | 6.50 | 7.30 | 6 | 6 | 5.50 | 7.30 | |
Unrecognized Compensation Cost for Nonvested Stock-Based Awards($M) | 352 | 373 | 264 | 285 | 324 | 346 | 239 | 258 | 290 | 313 | 243 | 225 | |
Global Workforce Headcount (Total Employees)1 | |||||||||||||
Unrecognized Tax Benefits (UTB) Ending Balance($M) | 818 | 814 | 792 | 767 | 747 | 722 | 700 | 679 | 657 | 619 | 609 | 584 | |
Consolidated Net Sales (Revenue)($M)11 | 1,716 | 1,741 | 1,649 | 1,570 | 1,553 | 1,532 | 1,413 | 1,386 | 1,354 | 1,369 | 1,330 | 1,266 | |
Cost of Sales($M) | 369 | 392 | 363 | 343 | 345 | 344 | 302 | 292 | 263 | 276 | 287 | 251 | |
Gross Profit($M) | 1,346 | 1,349 | 1,286 | 1,227 | 1,208 | 1,188 | 1,111 | 1,094 | 1,092 | 1,094 | 1,043 | 1,015 | |
Research and Development Expenses($M) | 281 | 279 | 263 | 268 | 281 | 276 | 255 | 271 | 253 | 272 | 257 | 242 | |
Selling, General and Administrative Expenses($M) | 561 | 561 | 522 | 603 | 515 | 502 | 466 | 492 | 421 | 448 | 428 | 417 | |
Operating Income($M) | 299 | 513 | 478 | 151 | 307 | 411 | 395 | 313 | 351 | 367 | 349 | 347 | |
Income Before Provision for Income Taxes($M) | 363 | 520 | 459 | 90.4 | 348 | 400 | 434 | 390 | 403 | 384 | 371 | 367 | |
Provision for Income Taxes($M) | 61.8 | 278 | 78.3 | 26.2 | 56.1 | 64.3 | 70.3 | 45.1 | 40.7 | 20 | 46.3 | 34.1 | |
Net Income from Continuing Operations($M) | 301 | 241 | 381 | 68.3 | 292 | 336 | 365 | 345 | 364 | 365 | 326 | 333 | |
Income (Loss) from Discontinued Operations, Net of Tax($M) | 0 | 0 | 0 | 27 | -2 | -4.40 | -7.20 | 39.3 | 2,707 | 1 | 26.1 | 36.6 | |
Diluted Earnings Per Share (GAAP)($) | 0.53 | 0.42 | 0.66 | 0.50 | 0.56 | 0.61 | 0.65 | 5.13 | 0.61 | 0.58 | 0.61 | ||
Weighted-Average Diluted Shares Outstanding(M) | 578 | 578 | 581 | 586 | 588 | 588 | 598 | 604 | 604 | ||||
Total Assets($M)12 | 14,144 | 13,867 | 13,321 | 13,697 | 13,272 | 13,489 | 13,022 | 13,055 | 12,971 | 10,099 | 9,736 | 9,363 | |
Accounts Receivable, Net($M) | 785 | 770 | 776 | 660 | 693 | 697 | 669 | 609 | 716 | 778 | 818 | 772 | |
Inventories, Net($M) | 1,159 | 1,131 | 1,119 | 1,126 | 1,141 | 1,142 | 1,114 | 1,087 | 1,104 | 1,025 | 1,207 | 904 | |
Total Current Assets($M) | 7,248 | 6,819 | 6,229 | 6,739 | 6,359 | 6,577 | 6,213 | 6,285 | 6,728 | 4,516 | 4,171 | 4,036 | |
Property, Plant and Equipment, Net($M) | 1,858 | 1,842 | 1,823 | 1,812 | 1,743 | 1,727 | 1,698 | 1,686 | 1,676 | 1,640 | 1,768 | 1,591 | |
Goodwill($M) | 1,952 | 1,951 | 1,820 | 1,769 | 1,769 | 1,777 | 1,779 | 1,777 | 1,605 | 1,151 | 1,253 | 1,145 | |
Other Intangible Assets, Net($M) | 1,161 | 1,383 | 1,228 | 1,128 | 1,131 | 1,173 | 1,175 | 1,177 | 956 | 417 | 447 | 399 | |
Total Current Liabilities($M) | 1,577 | 1,508 | 1,409 | 1,814 | 1,588 | 1,405 | 1,395 | 1,505 | 1,944 | 1,217 | 1,111 | 1,195 | |
Long-Term Debt($M) | 599 | 599 | 599 | 598 | 598 | 598 | 598 | 598 | 598 | 597 | 597 | 597 | |
Total Liabilities($M) | 3,183 | 3,142 | 2,994 | 3,360 | 3,067 | 2,882 | 2,831 | 2,992 | 3,360 | 2,595 | 2,550 | 2,644 | |
Retained Earnings($M) | 15,171 | 14,863 | 14,621 | 14,241 | 14,149 | 13,858 | 13,525 | 13,167 | 12,781 | 9,711 | 9,344 | 8,992 | |
Treasury Stock, at Cost($M) | -7,809 | -7,668 | -7,514 | -7,092 | -7,050 | -6,456 | -6,451 | -6,192 | -6,090 | -5,183 | -5,025 | -5,025 | |
Total Edwards Lifesciences Stockholders' Equity($M) | 10,861 | 10,618 | 10,328 | 10,338 | 10,205 | 10,545 | 10,129 | 9,998 | 9,546 | 7,437 | 7,118 | 6,650 | |
Operating Cash Flow (Net Cash Provided by Operating Activities)($M)6 | 570 | 652 | 43.8 | 451 | 574 | 290 | 280 | -128 | 352 | 372 | -53.5 | 137 | |
Capital Expenditures($M) | 63.6 | 66.9 | 64.9 | 97.4 | 57.5 | 49.3 | 56 | 49.8 | 51.9 | 85.4 | 65.3 | 88.3 | |
Depreciation and Amortization($M) | 44.9 | 42.7 | 40.9 | 42.7 | 39.2 | 38.1 | 36.6 | 42.6 | 34.5 | 39.6 | 38.5 | 36.7 | |
Stock-Based Compensation Expense($M) | 46 | 42.2 | 45.4 | 39.2 | 41.1 | 37.5 | 40.2 | 31.7 | 35.2 | 37.3 | 44.6 | 30.5 | |
Purchases of Treasury Stock (Cash Flow)($M) | 139 | 153 | 422 | 40.6 | 589 | 5.50 | 259 | 100 | 901 | 158 | 0.20 | 448 | |
Net Cash Used in Investing Activities($M) | -256 | -193 | -92.8 | -198 | -428 | -172 | 85.3 | -577 | 2,702 | 125 | 63.1 | 14.1 | |
Net Cash Used in Financing Activities($M) | -101 | -0.30 | -451 | -11.4 | -740 | 52.7 | -258 | 28.6 | -977 | -96.6 | 61.7 | -413 | |
8 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Structural Heart Drivers (Groups 1–5): Product group sales and constant-currency (underlying) growth rates across Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT, including standalone Implantable Heart Failure Management / Cordella revenue), Surgical Structural Heart (including Transitional Service Agreement revenue), and legacy Critical Care; regional sales and constant-currency growth across the United States, Europe, Japan, Rest of World, and Total OUS; ASU 2023-07 geographic operating segment cost of sales, other segment items, and long-lived assets; Non-GAAP operating statistics; and U.S. FDA PMA approvals, 510(k) clearances, MAUDE adverse event reports, and NIH ClinicalTrials.gov trial initiations.
- Critical Care Divestiture & Continuing Operations Restatement: On September 3, 2024 (Q3 2024), Edwards Lifesciences completed the sale of its Critical Care product group to Becton, Dickinson and Company (BD) for $4.2 billion. Filings from Q3 2024 onward report continuing operations (excluding Critical Care); historical Critical Care series are preserved through Q1/Q2 2024 as legacy series, and period splits strictly enforce same-basis accounting.
- Consolidated vs. Parent-Only Assessment: Edwards Lifesciences Corporation files under U.S. GAAP (Form 10-K/10-Q) without separate parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Subsidiary footprint is captured via Form 10-K Exhibit 21.1 significant subsidiary counts (U.S. vs. international) and standalone product footnote disclosures (IHFM / Cordella and Surgical TSA).
- Period Splitting: Q4 values for 10-K/10-Q cumulative tables and cash flow / footnote quarters (Q2–Q4) are derived strictly via FY − 9M or YTD − prior YTD on the same accounting basis.
Không hiện vì thiếu các kỳ gần đây (50)
- Unit Volume / Valve Implant Procedure Counts — Edwards Lifesciences does not disclose quarterly or annual unit sales volumes or exact commercial implant counts by therapy line (reporting only cumulative historical milestones such as >1.2 million cumulative SAPIEN patients treated globally).
- Cumulative SAPIEN Patients Treated (>1.2 million) — Excluded as a bound figure ('more than 1.2 million patients') rather than an exact point time series.
- Every Heartbeat Matters Cumulative Underserved Patients Impacted (>2.0 million in 2020–2024; >1.7 million in 2014–2020) — Excluded as cumulative multi-year bound figures ('over 2 million').
- 2023 Workplace Recordable & Lost Time Incident Rates — Omitted in the 2023 Corporate Impact Report (which reprinted 2022 safety figures on page 60 before resuming 2024 reporting in the 2024 report).
- Structural Heart Product Group Performance & Underlying Growth › Critical Care Sales (Legacy — Divested Sept 3, 2024) — Discontinued or non-continuous series across required latest periods
- Geographic Operating Segment Cost of Sales, Other Segment Items & Long-Lived Assets (ASU 2023-07) › Long-Lived Assets by Geographic Region — Total › Long-Lived Assets — United States — Discontinued or non-continuous series across required latest periods
- Geographic Operating Segment Cost of Sales, Other Segment Items & Long-Lived Assets (ASU 2023-07) › Long-Lived Assets by Geographic Region — Total › Long-Lived Assets — Outside of the United States (International) — Discontinued or non-continuous series across required latest periods
- Geographic Operating Segment Cost of Sales, Other Segment Items & Long-Lived Assets (ASU 2023-07) › Long-Lived Assets by Geographic Region — Total › Long-Lived Assets — Japan — Discontinued or non-continuous series across required latest periods
- Geographic Operating Segment Cost of Sales, Other Segment Items & Long-Lived Assets (ASU 2023-07) › Long-Lived Assets by Geographic Region — Total — Discontinued or non-continuous series across required latest periods
- FDA Regulatory Activity, Post-Market Surveillance (openFDA) & Clinical Trials (ClinicalTrials.gov) › NIH ClinicalTrials.gov Cumulative Registered Clinical Studies — Edwards Lifesciences › New Clinical Trials Initiated (By Study Start Date) — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross › Buildings and Leasehold Improvements, Gross — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross › Machinery and Manufacturing Equipment, Gross — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross › Construction in Progress (New Plants & Cleanroom Capacity Expansion) — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross › Land — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross › Accumulated Depreciation — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Property, Plant and Equipment, Gross — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Operating Lease Right-of-Use (ROU) Assets › Total Operating Lease Liabilities (Current & Noncurrent) — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Operating Lease Right-of-Use (ROU) Assets › Operating Lease Cost — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Operating Lease Right-of-Use (ROU) Assets › Operating Lease Weighted-Average Discount Rate — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Operating Lease Right-of-Use (ROU) Assets › Undiscounted Future Operating Lease Payments — Total — Discontinued or non-continuous series across required latest periods
- Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain › Operating Lease Right-of-Use (ROU) Assets › Unconditional Purchase Obligations (Materials & Services) — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Developed Technology Intangible Assets, Gross — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Patents Intangible Assets, Gross — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Other Finite-Lived Intangible Assets, Gross — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › In-Process Research and Development (IPR&D) Indefinite-Lived Intangible Assets — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Total Finite-Lived Intangible Assets, Gross — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Finite-Lived Intangible Assets Accumulated Amortization — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Total Finite-Lived Intangible Assets, Net — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Intangible Assets Amortization Expense — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Estimated Future Intangible Amortization Expense — Year 1 — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Estimated Future Intangible Amortization Expense — Year 2 — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Estimated Future Intangible Amortization Expense — Year 3 — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Estimated Future Intangible Amortization Expense — Year 4 — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Total Intangible Assets, Net (Finite-Lived & Indefinite-Lived IPR&D) › Estimated Future Intangible Amortization Expense — Year 5 — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Accrued Clinical Trial & Research and Development Liabilities › Accrued Marketing, Selling and Administrative Liabilities — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Accrued Clinical Trial & Research and Development Liabilities › Accrued Professional Services & Legal Fees — Discontinued or non-continuous series across required latest periods
- Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals › Accrued Clinical Trial & Research and Development Liabilities › Restructuring & Separation Charges — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Common Shares Repurchased (Monthly & Quarterly) › Average Price Paid per Repurchased Share — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › SBC Expense — Selling, General and Administrative — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › SBC Expense — Research and Development — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › SBC Expense — Cost of Sales — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › Restricted Stock Units (RSUs) Granted (Shares) — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › Performance-Based Restricted Stock Units (PBRSUs) Granted (Shares) — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › Stock Options Granted (Shares) — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › Stock Options Granted Weighted-Average Exercise Price — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Total Stock-Based Compensation (SBC) Expense › Stock Options Exercised Aggregate Intrinsic Value — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Global Workforce Headcount (Total Employees) › Defined Benefit Pension Plans Projected Benefit Obligation (PBO) — Discontinued or non-continuous series across required latest periods
- Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance › Global Workforce Headcount (Total Employees) › Defined Benefit Pension Plans Fair Value of Plan Assets — Discontinued or non-continuous series across required latest periods
- Segment & Geographic Revenue Context (Database) › Product Segment Revenue — Critical Care (Discontinued Sept 2024) — Discontinued or non-continuous series across required latest periods
- Consolidated Financial Statements Context (Database) › Consolidated Net Sales (Revenue) › Net Income Attributable to Edwards Lifesciences — Discontinued or non-continuous series across required latest periods
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Structural Heart Product Group Performance & Underlying Growth
- Total Continuing Operations Net Sales (Product Reconciliation) ($M)55 kỳ
- Transcatheter Aortic Valve Replacement (TAVR) Sales ($M)48 kỳ
- Transcatheter Mitral and Tricuspid Therapies (TMTT) Sales ($M)35 kỳ
- Surgical Structural Heart Sales ($M)48 kỳ
- Critical Care Sales (Legacy — Divested Sept 3, 2024) ($M)0 kỳ
Geographic Sales & Constant-Currency Growth by Region
Geographic Operating Segment Cost of Sales, Other Segment Items & Long-Lived Assets (ASU 2023-07)
Operating Statistics (% of Sales) & Non-GAAP Financial Performance
FDA Regulatory Activity, Post-Market Surveillance (openFDA) & Clinical Trials (ClinicalTrials.gov)
Manufacturing Inventory, Consignment Stock, Facilities & Supply Chain
Intangible Assets, M&A Amortization Schedule & Commercial / Legal Accruals
Share Repurchases, Stock-Based Compensation, Workforce & Corporate Governance
Corporate Impact, Environmental Sustainability, Workplace Safety & Philanthropy
Federal Healthcare Contracts (USAspending.gov) & U.S. Healthcare Macro Benchmarks (FRED)
Segment & Geographic Revenue Context (Database)
- Product Segment Revenue — Transcatheter Aortic Valve Replacement (TAVR) ($M)33 kỳ
- Product Segment Revenue — Transcatheter Mitral and Tricuspid Therapies (TMTT) ($M)33 kỳ
- Product Segment Revenue — Surgical Structural Heart ($M)33 kỳ
- Geographic Revenue — United States ($M)33 kỳ
- Geographic Revenue — Europe ($M)33 kỳ
- Geographic Revenue — Japan ($M)33 kỳ
- Geographic Revenue — Rest of World ($M)33 kỳ
Consolidated Financial Statements Context (Database)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Edwards Lifesciences
- SEC Filing (0001099800-26-000054) ↗
- Form 8-K (FY2026Q3 Earnings Release) ↗
- Form 8-K (FY2025Q4 Earnings Release) ↗
- SEC Filing (0001099800-26-000009) ↗
- Form 10-Q (filed 2026-11-04) ↗
- Form 10-K (filed 2026-02-25) ↗
- Form 10-K (FY2025) ↗
- Form 10-Q (FY2026Q3) ↗
- Edwards Lifesciences 2024 Corporate Impact Report ↗
- U.S. NIH ClinicalTrials.gov Registry (Edwards Lifesciences Sponsored & Collaborated Studies) ↗
- Form SD / Conflict Minerals Report (FY2025) ↗
- Edwards Lifesciences 2023 Corporate Impact Report ↗
See a number that looks wrong?